KAZIA THERAPEUTICS LTD (KZIA) Form 6-K — Sep 22, 2026

$KZIAForm 6-KFiled Sep 22, 2026, 8:00 AM ET0001213900-26-101967Original filing

Kazia Therapeutics announced that its Korean licensee Sovargen has dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders (focal cortical dysplasia type 2 and tuberous sclerosis complex). The dosing triggers a $2 million development milestone payment to Kazia, with up to $17 million in additional milestones plus royalties and sub-licensing revenue still available under the March 2024 licensing agreement.

Key figures

Trial phase: Phase 1b/2a
License agreement date: March 2024
Milestone payment triggered: $2 million
Remaining milestones potential: $17 million

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.